Gain Therapeutics' lead drug candidate, GT-02287, is in clinical development for the treatment of Parkinson's disease (PD) with or without a GBA1 mutation. The orally administered, brain-penetrant ...

Exxon is best-positioned among integrated oil firms for a potential downturn, given its underlying earnings growth and strong balance sheet. We sell different types of products and services to ...

NATICK, Mass., April 28, 2025 /PRNewswire/ -- AffyImmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced an abstract detailing its affinity-tuned CAR T therapy ...

"We are very pleased to receive confirmation that new clinical data for givastomig has been accepted as an oral presentation at the upcoming ESMO Gastrointestinal Cancers Congress 2025. As more ...

Details of the oral and poster presentation are as follows: Presentation Title: GT-02287, A Clinical-stage Allosteric GCase Modulator For The Treatment Of Parkinson's Disease, Protects Dopaminergic ...

The presentation introduces Virtual Reality Simulation (VRS) scenarios developed as part of an ERASMUS+ funded trans-European project – “ViReTrain, Virtual Reality Training for Health Professionals”.

The Emergency Medicine Registrar Ready course is designed for ST3 level EM trainees to prepare them for Higher Specialty Training when they will be the senior decision maker out of hours. To ensure ...

CDCP members who currently have coverage under the plan need to renew their coverage before June 1, 2025, for the new 2025 to 2026 coverage period.